Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
5(100.0%)
5Total
Phase 1(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06888921Phase 1Recruiting

A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer

Role: lead

NCT06759649Phase 1Recruiting

A Clinical Trial to Assess COM503 in Participants With Advanced Solid Malignancies

Role: lead

NCT04354246Phase 1Active Not Recruiting

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Role: lead

NCT03667716Phase 1Completed

COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.

Role: lead

NCT04570839Phase 1Completed

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Role: lead

All 5 trials loaded